Abstract
Digestive endoscopy has been proven to produce aerosols (1–3). This represents a risk of infection by COVID-19 and other airborne viruses. A number of protective barriers have been proposed to minimise that risk. Continuous suction of the oral cavity (1), shielding barriers (4,5), masks (6,7), and increasing the distance between patient and endoscopist (8) have been proposed as methods to reduce the exposure of endoscopists and endoscopy staff to aerosols. Here, we present a study that uses modified bronchoscopy masks (Explorer endoscopy facemask, Intersurgical Ltd., United Kingdom) to attenuate aerosol production at the patient’s mouth (bare mask shown in Fig. 1a and in use during an upper GI endoscopy in Fig. 1b). We find that this approach offers 47% (p=0.01) reduction in particle count for particles <5μm in diameter (i.e. aerosols), which are known to spread SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors also thank Nottingham University Hospitals NHS Trust for funding the rental of a particle counter, Norgine Pharmaceuticals for sponsoring the purchase of a particle counter. GSDG would like to acknowledge a UKRI Future Leaders Fellowship (MR/T041951/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Research Authority and ethical approval was granted by the Wales Research Ethics Committee prior to the start of the study (Integrated Research Application System no. 285595)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
frankmphillips{at}hotmail.com
Jane.Crowley{at}nottingham.ac.uk
Samantha.Warburton{at}nuh.nhs.uk
FUNDING The authors also thank Nottingham University Hospitals NHS Trust for funding the rental of a particle counter, Norgine Pharmaceuticals for sponsoring the purchase of a particle counter. GSDG would like to acknowledge a UKRI Future Leaders Fellowship (MR/T041951/1).
DATA AVAILABILITY STATEMENT Data associated with this publication is available at http://dx.doi.org/10.17639/nott.7112 Code used for data analysis in this publication can be found at https://github.com/gsdgordon/aerosols
CONFLICTS OF INTERESTS None declared.
Data Availability
Data associated with this publication is available at http://dx.doi.org/10.17639/nott.7112 Code used for data analysis in this publication can be found at https://github.com/gsdgordon/aerosols
